Barclays PLC Biovie Inc. Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.4 - $0.56 $3,464 - $4,850	-8,662 Reduced 77.63%	2,496 $1,000
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $3,425 - $12,215	-6,463 Reduced 36.68%	11,158 $6,000
Q4 2023 Feb 15, 2024	BUY	$1.22 - $5.24 $20,177 - $86,664	16,539 Added 1528.56%	17,621 $22,000
Q3 2023 Nov 07, 2023	BUY	$2.75 - $5.17 $1,058 - $1,990	385 Added 55.24%	1,082 $3,000
Q2 2023 Aug 03, 2023	SELL	$4.09 - $8.29 $218,487 - $442,851	-53,420 Reduced 98.71%	697 $3,000
Q1 2023 May 04, 2023	BUY	$4.89 - $10.53 $143,100 - $308,149	29,264 Added 117.75%	54,117 $437,000
Q4 2022 Feb 13, 2023	BUY	$3.86 - $42.0 $95,932 - $1.04 Million	24,853 New	24,853 $193,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $92M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.